During the past decade, Centre de Recherche Dermatologique du Quebec metropolitain conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 24 clinical trials were completed, i.e. on average, 96% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 17 clinical trials were completed. i.e. 141.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre de Recherche Dermatologique du Quebec metropolitain" #1 sponsor was "Pfizer" with 16 trials, followed by "Innovaderm Research Inc." with 6 trials sponsored, "Amgen" with 2 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "Concert Pharmaceuticals" with 2 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre de Recherche Dermatologique du Quebec metropolitain" #1 collaborator was "Amgen" with 4 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Innovaderm Research Inc." with 1 trials as a collaborator, "Janssen-Ortho LLC" with 1 trials as a collaborator and "Schering-Plough" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Centre de Recherche Dermatologique du Quebec metropolitain" are "Psoriasis" (11 trials), "Atopic Dermatitis" (9 trials), "Dermatitis, Atopic" (5 trials), "Alopecia Areata" (4 trials) and "Plaque Psoriasis" (3 trials). Many other conditions were trialed in "Centre de Recherche Dermatologique du Quebec metropolitain" in a lesser frequency.

Most popular intervention types in "Centre de Recherche Dermatologique du Quebec metropolitain" are "Drug" (42 trials), "Other" (8 trials), "Biological" (3 trials), "Device" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Apremilast" (3 trials), "CP-690,550" (3 trials), "Abrocitinib 200 mg" (2 trials) and "BMS-986165" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centre de Recherche Dermatologique du Quebec metropolitain" are 46 trials for "All" genders.

Currently, there are NaN active trials in "Centre de Recherche Dermatologique du Quebec metropolitain". undefined are not yet recruiting, 1 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 32 completed trials in Centre de Recherche Dermatologique du Quebec metropolitain, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Centre de Recherche Dermatologique du Quebec metropolitain, 2 "Phase 1" clinical trials were conducted, 22 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".